Department of Drug Metabolism and Pharmacokinetics, Biogen Idec, 14 Cambridge Center, Cambridge, MA 02142, USA.
Drug Metab Dispos. 2012 Apr;40(4):779-87. doi: 10.1124/dmd.111.043703. Epub 2012 Jan 19.
The objectives of the study were to characterize the selectivity of dantrolene to breast cancer resistance protein (Bcrp) and to evaluate whether cerebrospinal fluid (CSF) can be used as a surrogate to assess brain exposures of BCRP and P-glycoprotein (Pgp) substrates. The impact of Bcrp and Pgp on dantrolene exposures in brain and CSF was examined in Bcrp and Mdr1a/1b knockout mice and was further investigated in wild-type mice in the presence of the Bcrp inhibitor (3S,6S,12aS)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester (Ko143), the Pgp inhibitor 6-[(2S,4R,6E)-4-methyl-2-(methylamino)-3-oxo-6-octenoic acid]-7-l-valine-cyclosporine A (PSC833), and the dual inhibitor N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918). The effect of Bcrp and Pgp on digoxin exposures in brain and CSF was investigated in wild-type mice in the presence of the inhibitors. In vivo studies showed dantrolene exposures in brain and CSF, but not the blood, increased in Bcrp(-/-) and Mdr1a/1b(-/-)/Bcrp(-/-) mice, or in the presence of the Bcrp inhibitors Ko143 or GF120918. Inhibition of Pgp by GF120918 and PSC833 significantly increased digoxin exposures in brain, CSF, and blood to a lesser extent. Results from the present study demonstrated that inhibition of Bcrp and Pgp increased not only the exposures of dantrolene and digoxin in brain, but also the exposures in CSF. In addition, the change of exposures in CSF reflected the changes in brain. The present study strongly suggests that the dantrolene and digoxin exposures in CSF are primarily determined by the rapid transport from brain to CSF, and inhibition of Bcrp and Pgp exhibits little impact on using CSF as surrogates to assess brain exposures of Bcrp and Pgp substrates.
本研究的目的是描述丹曲林钠对乳腺癌耐药蛋白(Bcrp)的选择性,并评估脑脊液(CSF)是否可作为评估 Bcrp 和 P-糖蛋白(Pgp)底物脑暴露的替代物。在 Bcrp 和 Mdr1a/1b 敲除小鼠中,考察了 Bcrp 和 Pgp 对丹曲林钠在脑和 CSF 中暴露的影响,并在存在 Bcrp 抑制剂(3S,6S,12aS)-1,2,3,4,6,7,12,12a-八氢-9-甲氧基-6-(2-甲基丙基)-1,4-二氧代吡嗪[1',2':1,6]吡啶并[3,4-b]吲哚-3-丙酸 1,1-二甲基乙基酯(Ko143)、Pgp 抑制剂 6-[(2S,4R,6E)-4-甲基-2-(甲氨基)-3-氧代-6-辛烯酸]-7-L-缬氨酸环孢菌素 A(PSC833)和双重抑制剂 N-(4-[2-(1,2,3,4-四氢-6,7-二甲氧基-2-异喹啉基)乙基]-苯基)-9,10-二氢-5-甲氧基-9-氧代-4-吖啶羧酸酰胺(GF120918)的情况下,研究了抑制剂对地高辛在脑和 CSF 中暴露的影响。在存在抑制剂的情况下,在野生型小鼠中研究了 Bcrp 和 Pgp 对地高辛在脑和 CSF 中的暴露的影响。体内研究表明,丹曲林钠在脑和 CSF 中的暴露增加,但在 Bcrp(-/-)和 Mdr1a/1b(-/-)/Bcrp(-/-)小鼠中或在 Bcrp 抑制剂 Ko143 或 GF120918 存在的情况下,在血液中没有增加。Pgp 的抑制作用由 GF120918 和 PSC833 显著增加地高辛在脑、CSF 和血液中的暴露程度较小。本研究结果表明,Bcrp 和 Pgp 的抑制不仅增加了丹曲林钠和地高辛在脑内的暴露,而且增加了在 CSF 中的暴露。此外,CSF 中暴露的变化反映了脑内的变化。本研究强烈表明,CSF 中的丹曲林钠和地高辛暴露主要由从脑到 CSF 的快速转运决定,并且 Bcrp 和 Pgp 的抑制对使用 CSF 作为评估 Bcrp 和 Pgp 底物脑暴露的替代物影响不大。